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journa l homepage: www.cancerepidemiology.netMost cancer disparities research has traditionally focused on
two key outcomes, access to appropriate treatment and survival.
While continuing research on these two measures remains critical,
they do not encompass important aspects of patient-centred care
such as the timeliness of diagnosis and treatment [1]. Prolonged
time intervals between symptom onset and treatment initiation
increase the risk of poorer clinical outcomes and are associated
with worse patient experience of subsequent cancer care [2,3].
Studies examining inequalities in the timeliness of diagnosis and
treatment are therefore particularly welcome.
In this Journal, Nadpara et al. examined intervals to lung cancer
diagnosis, treatment, and associations between timely treatment
on mortality [4]. They used linked data from the Surveillance
Epidemiology and End Results (SEER)-Medicare database on nearly
50,000 US patients who were diagnosed with lung cancer during
2002–2007 and were 65 years of age or older. The authors
estimated the time of symptom onset based on the date of
Medicare consultation claims with ICD-9 codes denotingDOI of original article: http://dx.doi.org/10.1016/j.canep.2015.06.005
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in the patients’ SEER records about the approximate timing of
diagnosis. The latter source also provided information about the
timing and nature of treatment, and survival.
The investigators report a median diagnostic interval (between
ﬁrst symptomatic presentation and diagnosis) of about 180 days;
further, more than one in four patients experienced diagnostic
intervals exceeding 300 days [4]. Relatedly, a median diagnostic
interval of 113 days (with an upper quartile value of 249 days) was
reported by a recent English primary care records study of lung
cancer patients diagnosed during 2007–2010 and aged over 40 [5].
These alarmingly long diagnostic intervals observed on both sides
of the Atlantic reﬂect the symptom signature of lung cancer which
is dominated by symptoms of low predictive value, making lung
cancer one of the ‘harder-to-suspect’ malignancies [6]. For
example, possible lung cancer symptoms such as persistent cough
and dyspnoea have low speciﬁcity and are difﬁcult to distinguish
from manifestations of chronic pulmonary disease in smokers.
Conversely, haemoptysis, a classic ‘red ﬂag’ symptom with
relatively high predictive value, only occurs in a minority of
patients [7]. Tellingly, the proportion of patients with haemoptysis
in the reviewed study was so small that count data had to be
suppressed for information governance purposes [4].le under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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intervals by age and sex. Older patients had longer median
diagnostic intervals (e.g., 213 vs 146 days for 80+ and 65–69 year
olds, respectively), and this was also seen in women (209 vs 162
days in men) [4]. Concordant patterns of variation have been
described previously, but the age and sex inequalities in diagnostic
timeliness reported by this US study are particularly large [5]. The
observed steep age gradients may in part reﬂect greater diagnostic
challenges in patients with a higher burden of comorbidity.
Nevertheless future research to elucidate possible responsible
mechanisms is a relative priority.
Unusually for studies in this ﬁeld, the investigators examined
variation in delays to both diagnosis and treatment. Perhaps
unsurprisingly, intervals from diagnosis to treatment were
substantially shorter than intervals from symptom onset to
diagnosis, with median intervals from diagnosis to treatment
initiation of 27 and 18 days for patients with non-small cell and
small cell lung cancer, respectively [4]. Reassuringly, and in spite of
their sizeable inﬂuence on timeliness of diagnosis, patient
characteristics such as age, sex and comorbidity status had little
inﬂuence on the timeliness of treatment initiation. Concordantly,
evidence from England indicates that performance status, stage at
diagnosis, and lung cancer type have much greater effects on
treatment timeliness than socio-demographic factors [8].
The ﬁndings regarding delays from diagnosis to treatment
amplify recent relevant evidence for patients with lung and other
common cancers [9–13]. In addition to causing concern for
patients and their carers, post-diagnostic delays signal system-
level inefﬁciencies in cancer care. Increasingly, functional imaging
PET–CT investigations and biomarker proﬁling tests (e.g. to
ascertain tumour EGFR status) are being used to guide decisions
on optimal treatment for patients with lung cancer. Unfortunately,
these novel diagnostic technologies that can ‘personalise’ man-
agement options could substantially increase intervals from
diagnosis to treatment [14,15]. These considerations present
challenges for health policy planners and decision makers and
identify the need for streamlining and integrating care pathways
and services for cancer patients after diagnosis. Doing so can help
to improve both treatment timeliness and healthcare system
efﬁciency.
Deﬁning treatment timeliness can be difﬁcult. Nadpara et al.
operationally deﬁned untimely treatment as receipt of surgery,
radiotherapy, or chemotherapy after 8, 7, and 6 weeks, respectively,
based on guidelines from the British Thoracic Society and the
RAND Corporation. While these externally validated standards can
be used to ‘benchmark’ practice, deﬁning timeliness as a binary
outcome has limitations, given the continuous nature of this
measure and that many patients experience particularly long
delays. As the authors also remark, guideline-based deﬁnitions of
timeliness vary in the length of periods of time within which care is
judged as ‘timely’, while previous data-driven approaches have
used 95th centile cut-offs to deﬁne untimely treatment [11].
Development of further methodological consensus is needed in
this area. Considering the precise types of chemotherapy,
radiotherapy or surgery, and palliative or curative treatment
intent in future studies will be useful.
The study identiﬁed lung cancer type and stage at diagnosis as
strong independent predictors of timely diagnosis and treatment:
patients with small cell lung cancer or advanced stage at diagnosis
were more likely to have shorter pre-diagnostic intervals and to
start treatment promptly [4]. Further, patients with shorter
intervals to treatment had poorer survival. These ﬁndings concord
with the ‘waiting time paradox’ (or ‘sicker–quicker’) hypothesis,
where patients with most severe symptoms experience the
shortest delays in diagnosis or treatment and have worse survival
[2,8].Epidemiological studies using administrative data can describe
patterns of variation in diagnostic and treatment processes and
outcomes precisely, but cannot identify the exact causes of such
variations. Diagnostic delays are often generated by multiple pre-
diagnostic consultations, which occur in at least a third of all
patients subsequently diagnosed with lung cancer [16]. In other
instances, clinically appropriate investigations may not be ordered
or, if ordered, they may be a source of additional delays [17,18].
Further, small proportions of patients may have expressed
preferences for delayed investigations or decline referral [19].
The obviously diverse nature of ‘missed opportunities’ for
suspecting lung cancer makes clinical audit studies that are based
on case-record reviews a necessary supplement to epidemiological
studies in order to identify targets for improvement interventions
[20,21]. Similar approaches are needed to study mechanisms
leading to potentially avoidable delays from diagnosis to treat-
ment.
The commented study poignantly demonstrates that the
fundamental challenges in promptly diagnosing and treating
patients with cancer transcend healthcare systems worldwide. In
recent years, major research initiatives hosted within the
International Cancer Benchmarking Partnership have helped to
unearth a wealth of comparative evidence on cancer outcomes and
their determinants in countries with broadly similar healthcare
systems (Australia, Canada, Denmark, Norway, Sweden, and the
UK) [22]. Including data from patients treated by US population-
based healthcare providers in future international cancer out-
comes research consortia can provide additional insights into the
causes of diagnostic and treatment delays, accelerating the pace of
discovery and elucidating effective solutions to these universal
problems.
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